Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy
Background: Long-acting injectable medications have become an important tool in the treatment of schizophrenia and schizoaffective disorder due to the high rates of medication nonadherence. Olanzapine long-acting injection (OLAI) is a useful therapeutic option for patients who have good tolerability...
Main Authors: | Joshua Gerving, PharmD, BCPS, BCPP, Heather Walser, PharmD, BCPP, Anne C. Kelly, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association of Psychiatric Pharmacists
2023-08-01
|
Series: | Mental Health Clinician |
Subjects: | |
Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2022.08.263 |
Similar Items
-
Comparison of antipsychotic prescribing practices following failure of antipsychotic monotherapy in the acute care setting
by: Kaitlyn Morgan, PharmD, BCPP, et al.
Published: (2023-01-01) -
Antidepressant prescribing in transgender and nonbinary individuals diagnosed with gender dysphoria and mood or anxiety disorders
by: Casey M. Tiefenthaler, PharmD, BCPP, et al.
Published: (2023-12-01) -
Postinjection delirium/sedation syndrome with olanzapine depot injection
by: Sadhvi Mythili Sarangula, et al.
Published: (2016-01-01) -
Comparison of inpatient psychiatric medication management in gender diverse youth with cisgender peers
by: Carrillo Nina PharmD, et al.
Published: (2023-08-01) -
Quetiapine and olanzapine misuse prevalence in a US general population sample
by: Kirk E Evoy, PharmD, BCACP, BC-ADM, CTTS, et al.
Published: (2023-04-01)